A Randomised, Prospective Study, Assessing Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa. (CogUK)

NCT01367236 Phase 4 COMPLETED Results posted

The purpose of this study is to compare two different combination anti-HIV therapies over 48 weeks and to assess if differences in improvement in the function of the brain are observed over this period. The study will compare anti-HIV therapy combinations which are currently in use. The patients will not have had any previous treatment for their HIV infection.

Details

Lead sponsor	Imperial College London
Phase	Phase 4
Status	COMPLETED
Enrolment	60
Start date	2013-01
Completion	2015-10

Conditions

• HIV
• Impaired Cognition

Interventions

• standard care
• novel treatment

Primary outcomes

• Cognitive Function, Global Cognitive Score (Z-score) — 24 weeks, 48 weeks
  When commencing antiretroviral therapy (anti-HIV therapy) for the first time, improvements in the function of the brain are frequently observed. For example memory and concentration may improve. However, whether these improvements may differ between different anti-HIV therapies is largely unknown. The purpose of this study is to compare two different combination anti-HIV therapies over 48 weeks and to assess if differences in improvement in the function of the brain are observed over this period. Score increase means improved performance of cognitive function

Countries

United Kingdom